Evidence map›Paper›PMID 40970356›Full record

ArticleOncology reports2025

Senescence‑associated IL‑33 secretion undermines sorafenib efficacy in hepatocellular carcinoma via immune evasion.

Yu-Xin Lin, Hsien Liu, Wei-Chiao Liao, Yi-Ching Wang, Bo-Cheng Zhang, Shu-Wen Wan, Chien-Chin Chen, Chih-Peng Chang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yu-Xin Lin *Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
Hsien Liu *Division of General Surgery, Department of Surgery, Ditmanson Medical Foundation Chia‑Yi Christian Hospital, Chiayi 60002,Taiwan.
Wei-Chiao LiaoDepartment of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
Yi-Ching WangInstitute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
Bo-Cheng ZhangDepartment of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
Shu-Wen WanDepartment of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
Chien-Chin ChenDepartment of Pathology, Ditmanson Medical Foundation Chia‑Yi Christian Hospital, Chiayi 60002, Taiwan.
Chih-Peng ChangDepartment of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a highly lethal cancer with increasing incidence rates worldwide. The recommended treatments for advanced‑stage HCC are sorafenib and regorafenib; however, developing resistance to these medications significantly limits their effectiveness, and the underlying mechanisms are poorly understood. The present study demonstrated that interleukin‑33 (IL‑33) promotes sorafenib resistance via immune regulation.

Indexed as

Carcinoma, HepatocellularDrug Resistance, NeoplasmInterleukin-33Liver NeoplasmsSorafenibAnimalsB7-H1 AntigenCell Line, TumorCell ProliferationCellular SenescenceGene Expression Regulation, NeoplasticHumansMaleMicePhenylurea CompoundsPyridinesB7-H1 AntigenCD274 protein, humanInterleukin-33Phenylurea CompoundsPyridinesregorafenibSorafenibhepatocellular carcinomainterleukin‑33programmed death ligand 1regorafenibsorafenib

Identifiers

PMID40970356
PMCPMC12456110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.